PHASE II STUDY OF TIRAPAZAMINE (NSC-13018)/CISPLATIN/ETOPOSIDE IN LUNG CANCER

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 本研究的目的是了解替拉帕胺、顺铂、依托泊苷联合放疗对小细胞肺癌患者的疗效。替拉帕扎明是一种试验性试剂。本研究的研究性质是在标准化疗和放射治疗的基础上增加替拉帕明。 除了这种治疗外，研究人员还将参与建立肺癌标本库，该标本库将存储肺癌患者的组织，供当前和未来的科学研究使用。 这项研究是在霍林斯癌症中心进行的，并要求提供不能通过MUSC提供的GCRC实验室服务，即需要冷藏离心机的标本的存储和样品处理。 2006年4月4日，本网站未有受试者报名参加本研究的报告。招聘工作正在进行中。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to find out what the effects, good and bad, the combination of tirapazamine, cisplatin, and etoposide with radiation therapy followed the combintation of cisplatin and etoposide has on patients with small cell lung cancer. Tirapazamine is an experimental agent. The investigationsl nature of this study is the addition of tirapazamine to standard chemotherpay and radiotherapy. In addition to this treatment, the investigators will take part in establishing a lung cancer specimen bank, which will store tissues from lung cancer patient to use in current and future scientific research studies. This study is being conducted at the Hollings Cancer Center, and are asking for GCRC lab services that cannot be provided through MUSC, which is storage and sample processing for specimens requiring a refrigerated centrifuge. 04/2006 There are no reports of subject enrolled at this site for this study. Recruitment is ongoing.